Skip to main content
Erschienen in: Immunologic Research 3/2016

22.01.2016 | Original Article

Primary immunodeficiencies worldwide: an updated overview from the Jeffrey Modell Centers Global Network

verfasst von: Vicki Modell, Jessica Quinn, Jordan Orange, Luigi D. Notarangelo, Fred Modell

Erschienen in: Immunologic Research | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Primary immunodeficiencies (PI) are defects of the immune system that cause severe, sometimes life-threatening, infections if not diagnosed and treated appropriately. Many patients with PI are undiagnosed, under-diagnosed, or misdiagnosed. To raise awareness and assure earliest diagnosis, appropriate treatment, and proper care management, the Jeffrey Modell Foundation (JMF) implemented a physician education and public awareness program beginning in 2003. Data are requested annually from physician experts within the Jeffrey Modell Centers Network (JMCN), consisting of 602 expert physicians, at 253 academic institutions, in 206 cities, and 84 countries spanning six continents. Center Directors reported on patients’ specific PI defects and treatment modalities including immunoglobulins, transplantation, and gene therapy as well as data on gender and age. Center Directors also provided physician-reported patient outcomes as well as pre- and post-diagnosis differences. Costs were assigned to these factors. In collaboration with the Network, JMF advocated, funded, and implemented population-based newborn screening for severe combined immunodeficiency and T cell lymphopenia, covering 96.2 % of all newborns in the US. Finally, 21 JMF Centers participated in a polio surveillance study of patients with PI who either received or have been exposed to the oral polio vaccine. These initiatives have led to an overall better understanding of the immune system and will continue to improve quality of life for those with PI.
Literatur
1.
Zurück zum Zitat Modell V. The impact of physician education and public awareness on early diagnosis of primary immunodeficiencies. Immunol Res. 2007;38:43–7.CrossRefPubMed Modell V. The impact of physician education and public awareness on early diagnosis of primary immunodeficiencies. Immunol Res. 2007;38:43–7.CrossRefPubMed
2.
Zurück zum Zitat Modell F. Immunology today and new discoveries: building upon legacies of Dr. Robert A. Good. Immunol Res. 2007;38:48–50.CrossRefPubMed Modell F. Immunology today and new discoveries: building upon legacies of Dr. Robert A. Good. Immunol Res. 2007;38:48–50.CrossRefPubMed
3.
Zurück zum Zitat Cunningham-Rundles C, Ponda PP. Molecular defects in T- and B-cell primary immunodeficiency diseases. Nat Rev Immunol. 2005;5:880–92.CrossRefPubMed Cunningham-Rundles C, Ponda PP. Molecular defects in T- and B-cell primary immunodeficiency diseases. Nat Rev Immunol. 2005;5:880–92.CrossRefPubMed
4.
Zurück zum Zitat Cooper MA, Pommering TL, Koranyi K. Primary immunodeficiencies. Am Fam Physician. 2003;68:2001–8.PubMed Cooper MA, Pommering TL, Koranyi K. Primary immunodeficiencies. Am Fam Physician. 2003;68:2001–8.PubMed
5.
Zurück zum Zitat Bousfiha A, Jeddane L, Al-Herz W, Ailal F, Casanova JL, Chatila T, Conley ME, Cunningham-Rundles C, Etzioni A, Franco JL, Gaspar HB, Holland SM, Klein C, Nonoyam S, Ochs HD, Oksenhendler E, Picard C, Puck JM, Sullivan K, Tang MLK. The 2015 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2015. doi:10.1007/s10875-015-0198-5. Bousfiha A, Jeddane L, Al-Herz W, Ailal F, Casanova JL, Chatila T, Conley ME, Cunningham-Rundles C, Etzioni A, Franco JL, Gaspar HB, Holland SM, Klein C, Nonoyam S, Ochs HD, Oksenhendler E, Picard C, Puck JM, Sullivan K, Tang MLK. The 2015 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2015. doi:10.​1007/​s10875-015-0198-5.
6.
Zurück zum Zitat Bousifiha AA, Jeddane L, Ailal F, Benhsaien I, Mahlaoui N, Casanova JL, Abel L. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol. 2013;33(1):1–7.CrossRef Bousifiha AA, Jeddane L, Ailal F, Benhsaien I, Mahlaoui N, Casanova JL, Abel L. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol. 2013;33(1):1–7.CrossRef
8.
Zurück zum Zitat Modell V, Gee B, Lewis DB, Orange JS, Roifman CM, Routes JM, Sorensen RU, Notarangelo LD, Modell F. Global study of primary immunodeficiency diseases (PI)—diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res. 2011;51:61–70.CrossRefPubMed Modell V, Gee B, Lewis DB, Orange JS, Roifman CM, Routes JM, Sorensen RU, Notarangelo LD, Modell F. Global study of primary immunodeficiency diseases (PI)—diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res. 2011;51:61–70.CrossRefPubMed
9.
Zurück zum Zitat Modell F, Puente D, Modell V. From genotype to phenotype. Further studies measuring the impact of a Physician Education and Public Awareness Campaign on early diagnosis and management of primary immunodeficiencies. Immunol Res. 2009;44(1–3):132–49.CrossRefPubMed Modell F, Puente D, Modell V. From genotype to phenotype. Further studies measuring the impact of a Physician Education and Public Awareness Campaign on early diagnosis and management of primary immunodeficiencies. Immunol Res. 2009;44(1–3):132–49.CrossRefPubMed
10.
Zurück zum Zitat Buckley RH, Schiff SE, Schif RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med. 1999;340(7):508–16.CrossRefPubMed Buckley RH, Schiff SE, Schif RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med. 1999;340(7):508–16.CrossRefPubMed
11.
Zurück zum Zitat Puck JM. Laboratory technology for population-based screening for severe combined immunodeficiency in neonates: the winner is T-cell receptor excision circles. J Allergy Clin Immunol. 2012;129(3):607–16. Puck JM. Laboratory technology for population-based screening for severe combined immunodeficiency in neonates: the winner is T-cell receptor excision circles. J Allergy Clin Immunol. 2012;129(3):607–16.
12.
Zurück zum Zitat Routes JM, Grossman WJ, Verbsky J, Laessig RH, Hoffman GL, Brokopp CD, Baker MW. Statewide newborn screening for severe T-cell lymphopenia. JAMA. 2009;302(22):2465–70.CrossRefPubMed Routes JM, Grossman WJ, Verbsky J, Laessig RH, Hoffman GL, Brokopp CD, Baker MW. Statewide newborn screening for severe T-cell lymphopenia. JAMA. 2009;302(22):2465–70.CrossRefPubMed
13.
Zurück zum Zitat Buckley RH. Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: longterm outcomes. Immunol Res. 2011;49:25–43.CrossRefPubMedPubMedCentral Buckley RH. Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: longterm outcomes. Immunol Res. 2011;49:25–43.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Myers LA, Patel DD, Puck JM, Buckley RH. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood. 2002;99:872–8.CrossRefPubMed Myers LA, Patel DD, Puck JM, Buckley RH. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood. 2002;99:872–8.CrossRefPubMed
15.
Zurück zum Zitat Patel NC, et al. Outcomes of severe combined immunodeficiency patients treated with hematopoietic stem cell transplantation with and without pre-conditioning. J Allergy Clin Immunol. 2009;124(5):1062–9.e1–4.CrossRef Patel NC, et al. Outcomes of severe combined immunodeficiency patients treated with hematopoietic stem cell transplantation with and without pre-conditioning. J Allergy Clin Immunol. 2009;124(5):1062–9.e1–4.CrossRef
16.
Zurück zum Zitat Antoine C, Muller S, Cant A, et al. Long-term survival and transplantation of hemopoietic stem cells for immunodeficiencies; report of the European experience 1986–1999. Lancet. 2003;361(9357):553–60.CrossRefPubMed Antoine C, Muller S, Cant A, et al. Long-term survival and transplantation of hemopoietic stem cells for immunodeficiencies; report of the European experience 1986–1999. Lancet. 2003;361(9357):553–60.CrossRefPubMed
17.
Zurück zum Zitat Hassan A, Booth C, Brightwell A, et al. Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. Blood. 2012;120(17):3615–24.CrossRefPubMed Hassan A, Booth C, Brightwell A, et al. Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. Blood. 2012;120(17):3615–24.CrossRefPubMed
19.
Zurück zum Zitat Diop OM, Burns CC, Sutter RW, Wassilak SG, Kew OM, Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses—worldwide, January 2014–March 2015. MMWR Morb Mortal Wkly Rep. 2015;64(23):640–6.PubMed Diop OM, Burns CC, Sutter RW, Wassilak SG, Kew OM, Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses—worldwide, January 2014–March 2015. MMWR Morb Mortal Wkly Rep. 2015;64(23):640–6.PubMed
20.
Zurück zum Zitat Guo J, Bolivar-Wagers S, Srinivas N, Holubar M, Maldonado Y. Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication. Vaccine. 2015;33:1235–42.CrossRefPubMed Guo J, Bolivar-Wagers S, Srinivas N, Holubar M, Maldonado Y. Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication. Vaccine. 2015;33:1235–42.CrossRefPubMed
21.
Zurück zum Zitat Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, Cunningham-Rundles C, Etzioni A, Holland SM, Klein C, Nonoyama S, Ochs HD, Oksenhendler E, Puck J, Sullivan KE, Tang MLK, Franco JL, Gaspar HB. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for primary immunodeficiency 2015. J Clin Immunol. 2015. doi:10.1007/s10875-015-0201-1. Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, Cunningham-Rundles C, Etzioni A, Holland SM, Klein C, Nonoyama S, Ochs HD, Oksenhendler E, Puck J, Sullivan KE, Tang MLK, Franco JL, Gaspar HB. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for primary immunodeficiency 2015. J Clin Immunol. 2015. doi:10.​1007/​s10875-015-0201-1.
22.
Zurück zum Zitat NIHCM Foundation. Employer-sponsored Health Insurance: Recent Trends and Future Directions. NIHCM Data Brief. 2013. NIHCM Foundation. Employer-sponsored Health Insurance: Recent Trends and Future Directions. NIHCM Data Brief. 2013.
27.
Zurück zum Zitat Bundorf KM, Royalty A, Baker LC. Health care cost growth among the privately insured. Health Aff. 2009;28(5):1294–304.CrossRef Bundorf KM, Royalty A, Baker LC. Health care cost growth among the privately insured. Health Aff. 2009;28(5):1294–304.CrossRef
28.
Zurück zum Zitat Truven Health Analytics. Healthcare Spending Index for Employer-Sponsored Insurance. 2014. Truven Health Analytics. Healthcare Spending Index for Employer-Sponsored Insurance. 2014.
32.
Zurück zum Zitat Fronstin P. Sources of health insurance and characteristics of the uninsured: analysis of the March 2013 current population survey, vol 390. EBRI (Employee Benefit Research Institute) Issue Brief No. 390, September 2013, Washington, DC; 2013. p. 1–36. Fronstin P. Sources of health insurance and characteristics of the uninsured: analysis of the March 2013 current population survey, vol 390. EBRI (Employee Benefit Research Institute) Issue Brief No. 390, September 2013, Washington, DC; 2013. p. 1–36.
33.
Zurück zum Zitat Chan K, Davis J, Pai SY, Bonilla FA, Puck JM, Apkon M. A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID). Mol Genet Metab. 2011;104(3):383–9.CrossRefPubMedPubMedCentral Chan K, Davis J, Pai SY, Bonilla FA, Puck JM, Apkon M. A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID). Mol Genet Metab. 2011;104(3):383–9.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Menzin J, Sussman M, Munsell M, Zbrozek A. Economic impact of infections among patients with primary immunodeficiency disease receiving IVIG therapy. Clinicoecon Outcomes Res. 2014;6:297–302.CrossRefPubMedPubMedCentral Menzin J, Sussman M, Munsell M, Zbrozek A. Economic impact of infections among patients with primary immunodeficiency disease receiving IVIG therapy. Clinicoecon Outcomes Res. 2014;6:297–302.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Denno MS, Popelar B, Abdel-Sattar M, et al. Managed care perceptions and utilization of outcomes analyzers in the United States. Poster presented at the Academy of Managed Care Pharmacy (AMCP) 26th Annual Meeting; Tampa, FL: 2014. Denno MS, Popelar B, Abdel-Sattar M, et al. Managed care perceptions and utilization of outcomes analyzers in the United States. Poster presented at the Academy of Managed Care Pharmacy (AMCP) 26th Annual Meeting; Tampa, FL: 2014.
37.
Zurück zum Zitat Sebelius K. Letter to the committee chairperson for the Secretary’s advisory committee on heritable disorders in newborns and children US Department of Health and Human Services. 2010. http://tinyurl.com/l9baeng. Sebelius K. Letter to the committee chairperson for the Secretary’s advisory committee on heritable disorders in newborns and children US Department of Health and Human Services. 2010. http://​tinyurl.​com/​l9baeng.
41.
Zurück zum Zitat Kuehn BM. State, federal efforts under way to identify children with ‘‘Bubble Boy Syndrome’’. JAMA. 2010;304(16):1771–3.CrossRefPubMed Kuehn BM. State, federal efforts under way to identify children with ‘‘Bubble Boy Syndrome’’. JAMA. 2010;304(16):1771–3.CrossRefPubMed
43.
Zurück zum Zitat Kwan A, Church JA, Cowan MJ, Agarwal R, Kapoor N, Kohn DB, Lewis DB, McGhee SA, Moore TB, Stiehm ER, Porteus M, Aznar CP, Currier R, Lorey F, Puck JM. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 years. J Allergy Clin Immunol. 2013;132(1):140–50.CrossRefPubMedPubMedCentral Kwan A, Church JA, Cowan MJ, Agarwal R, Kapoor N, Kohn DB, Lewis DB, McGhee SA, Moore TB, Stiehm ER, Porteus M, Aznar CP, Currier R, Lorey F, Puck JM. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 years. J Allergy Clin Immunol. 2013;132(1):140–50.CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Hospital Cost and Utilization Project (HCUP), Nationwide Inpatient Database under the auspices of the Agency for Healthcare Research and Quality (AHRQ). ICD-9 CM Principal Diagnosis Code for HSCT. Hospital Cost and Utilization Project (HCUP), Nationwide Inpatient Database under the auspices of the Agency for Healthcare Research and Quality (AHRQ). ICD-9 CM Principal Diagnosis Code for HSCT.
46.
Zurück zum Zitat Centers for Medicare and Medicaid Services, Hospital Accounting Records. 2010. Centers for Medicare and Medicaid Services, Hospital Accounting Records. 2010.
47.
Zurück zum Zitat Milner JD, Holland SM. The cup runneth over: lessons from the ever-expanding pool of primary immunodeficiency diseases. Immunology. 2013;13:635–48.PubMed Milner JD, Holland SM. The cup runneth over: lessons from the ever-expanding pool of primary immunodeficiency diseases. Immunology. 2013;13:635–48.PubMed
48.
Zurück zum Zitat Bharat ST, Alizadehfar R, Desrosiers M, Shuster J, Pant N, Tsoukasa CM. Adult primary immune deficiency: what are we missing? Am J Med. 2012;125(8):779–86.CrossRef Bharat ST, Alizadehfar R, Desrosiers M, Shuster J, Pant N, Tsoukasa CM. Adult primary immune deficiency: what are we missing? Am J Med. 2012;125(8):779–86.CrossRef
50.
Zurück zum Zitat Keller MD, Bollard CM, Hanley PJ, McCormack S, Heimall J, Bunin N, Loechelt B, Jyonouchi S. Viral-specific T lymphocytes for treatment of viral infections in primary immunodeficiency. Biol Blood Marrow Trans. 2015;21(2):S229–30.CrossRef Keller MD, Bollard CM, Hanley PJ, McCormack S, Heimall J, Bunin N, Loechelt B, Jyonouchi S. Viral-specific T lymphocytes for treatment of viral infections in primary immunodeficiency. Biol Blood Marrow Trans. 2015;21(2):S229–30.CrossRef
Metadaten
Titel
Primary immunodeficiencies worldwide: an updated overview from the Jeffrey Modell Centers Global Network
verfasst von
Vicki Modell
Jessica Quinn
Jordan Orange
Luigi D. Notarangelo
Fred Modell
Publikationsdatum
22.01.2016
Verlag
Springer US
Erschienen in
Immunologic Research / Ausgabe 3/2016
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-016-8784-z

Weitere Artikel der Ausgabe 3/2016

Immunologic Research 3/2016 Zur Ausgabe

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

HNO-Op. auch mit über 90?

16.04.2024 HNO-Chirurgie Nachrichten

Mit Blick auf das Risiko für Komplikationen nach elektiven Eingriffen im HNO-Bereich scheint das Alter der Patienten kein ausschlaggebender Faktor zu sein. Entscheidend ist offenbar, wie fit die Betroffenen tatsächlich sind.

Intrakapsuläre Tonsillektomie gewinnt an Boden

16.04.2024 Tonsillektomie Nachrichten

Gegenüber der vollständigen Entfernung der Gaumenmandeln hat die intrakapsuläre Tonsillektomie einige Vorteile, wie HNO-Fachleute aus den USA hervorheben. Sie haben die aktuelle Literatur zu dem Verfahren gesichtet.

Bilateraler Hörsturz hat eine schlechte Prognose

15.04.2024 Hörsturz Nachrichten

Die Mehrzahl der Menschen mit Hörsturz ist einseitig betroffen, doch auch ein beidseitiger Hörsturz ist möglich. Wie häufig solche Fälle sind und wie sich ihr Verlauf darstellt, hat eine HNO-Expertenrunde aus den USA untersucht.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.